1421593-80-7

Basic information

• Product Name: N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)acetamide
• CAS NO: 1421593-80-7
• Molecular Weight: 301.302
• Mol File: 1421593-80-7.mol
• Article Data: 3

Chemical Properties

• Melting Point: >264°C (dec.)
• Boiling Point: 679.7±55.0 °C(Predicted)
• Density: 1.446±0.06 g/cm3(Predicted)
• CAS DataBase Reference: N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)acetamide(1421593-80-7)
• EPA Substance Registry System: N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)acetamide(1421593-80-7)

Safety Data

• Hazardous Substances Data: 1421593-80-7(Hazardous Substances Data)

Usage

Uses

N-[2-(2,6-Dioxo-3-piperidinyl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-acetamide is a related compound of Lenalidomide (L328000), an immunomodulatory drug and an analog of Thalidomide.

Upstream product

• 827026-45-9 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione 
• 98475-07-1 2-bromomethyl-3-nitro-benzoic acid methyl ester 
• 59382-59-1 2-methyl-3-nitro-benzoic acid methyl ester 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 2353-44-8 (+/-)-α-aminoglutarimide 
• 31140-42-8 (RS)-(2,6-dioxopiperidin-3-yl)carbamic acid tert-butyl ester 
• 13726-85-7 Boc-Gln-OH 
• 75-36-5 acetyl chloride 
• 879126-98-4 Lenalidomide 

Relevant articles and documents

REGULATING CHIMERIC ANTIGEN RECEPTORS

This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

Design, synthesis and biological evaluation of Lenalidomide derivatives as tumor angiogenesis inhibitor

Lenalidomide is a type of immunomodulatory agent with anti-tumor activity by mainly expressed in the anti-angiogenesis. In order to enhance the pharmacological activity of Lenalidomide, a series of Lenalidomide derivatives were designed as tumor angiogenesis inhibitors. The potential anti-angiogenesis targets of Lenalidomide derivatives were virtual screened on Auto-Dock 4.0 by using reverse docking method. The six target proteins, such as vascular endothelial growth factor receptor, epidermal growth factor receptor, fibroblast growth factor receptor, BCR-ABL tyrosine kinase, p38 mitogen activated protein kinase and metal protein kinase, were chosen as the targets. The Lenalidomide derivatives were synthesized by alkylated, acylated or sulfonylated Lenalidomide and verified by the 1H NMR, 13C NMR and LC–MS. Their anti-cancer activities were detected by using CCK-8 in the esophageal carcinoma cell line EC9706. The results indicate that the inhibitory activities of Lenalidomide derivatives were higher than that of Lenalidomide.